- /
- Supported exchanges
- / US
- / DSNKY.PINK
Daiichi Sankyo Co Ltd ADR (DSNKY PINK) stock market data APIs
Daiichi Sankyo Co Ltd ADR Financial Data Overview
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It also provides Lixiana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis and bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer for the treatment of iron deficiency anemia; Vimpat, an anti-seizure medication; and Reyvow for the treatment of acute migraine attacks. Further, it provides Daichirona, a coronavirus RNA vaccine; Flumist, an intranasal live attenuated influenza vaccine; adsorbed cell culture-derived influenza vaccine; measles rubella combined vaccine; and mump vaccine. The company was formerly known as Sankyo Co. Ltd. and changed its name to Daiichi Sankyo Company, Limited in September 2005. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Daiichi Sankyo Co Ltd ADR data using free add-ons & libraries
Get Daiichi Sankyo Co Ltd ADR Fundamental Data
Daiichi Sankyo Co Ltd ADR Fundamental data includes:
- Net Revenue: 2 223 188 M
- EBITDA: 311 074 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Daiichi Sankyo Co Ltd ADR Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-07-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Daiichi Sankyo Co Ltd ADR News
New
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos
Summit Therapeutics SMMT is expanding the development of its sole investigational drug, ivonescimab, through a new clinical collaboration with AstraZeneca AZN and its Japan-based partner Daiichi Sanky...
Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration
In late September and early October 2026, AstraZeneca PLC, Daiichi Sankyo and Summit Therapeutics announced a series of clinical collaboration agreements to test ivonescimab in combination with Datrow...
Sector Update: Healthcare Stocks Steady Late Afternoon
Healthcare stocks were little changed late Friday afternoon with the NYSE Healthcare Index and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3
This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), the oncology and biopharmaceutical company, expanded its cancer-drug collaboration with Summit Therapeutics as U.S. shares edge a bit...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.